par  Berghmans, Thierry  ;Lafitte, Jean-Jacques;Scherpereel, Arnaud;Paesmans, Marianne
;Lafitte, Jean-Jacques;Scherpereel, Arnaud;Paesmans, Marianne  ;Lecomte, Jacques;Marco, Vicente Giner;Meert, Anne-Pascale
;Lecomte, Jacques;Marco, Vicente Giner;Meert, Anne-Pascale  ;Leclercq, Nathalie
;Leclercq, Nathalie  ;Sculier, Jean-Paul
;Sculier, Jean-Paul  ;European Lung Cancer Working Party,
;European Lung Cancer Working Party, 
Référence Anticancer research, 33, 12, page (5477-5482)
Publication Publié, 2013-12
           ;Lafitte, Jean-Jacques;Scherpereel, Arnaud;Paesmans, Marianne
;Lafitte, Jean-Jacques;Scherpereel, Arnaud;Paesmans, Marianne  ;Lecomte, Jacques;Marco, Vicente Giner;Meert, Anne-Pascale
;Lecomte, Jacques;Marco, Vicente Giner;Meert, Anne-Pascale  ;Leclercq, Nathalie
;Leclercq, Nathalie  ;Sculier, Jean-Paul
;Sculier, Jean-Paul  ;European Lung Cancer Working Party,
;European Lung Cancer Working Party, Référence Anticancer research, 33, 12, page (5477-5482)
Publication Publié, 2013-12
                                                                                                       
			Article révisé par les pairs
                                                  
        | Résumé : | Aim: While meta-analyses and clinical trials show improved survival in advanced NSCLC treated with platinum-containing chemotherapy, there are few data concerning front-line platinum-free ifosfamide-based regimens. We aimed to compare cisplatin-based chemotherapy to ifosfamide-gemcitabine (IG) with pre-defined second-line docetaxel. | 



